40
Participants
Start Date
May 19, 2014
Primary Completion Date
February 3, 2026
Study Completion Date
February 3, 2026
Carboplatin
Given IP or IV
Cisplatin
Given IP
Gemcitabine Hydrochloride
Given IP or IV
Laboratory Biomarker Analysis
Correlative studies
Paclitaxel
Given IP or IV
Pegylated Liposomal Doxorubicin Hydrochloride
Given IP or IV
Quality-of-Life Assessment
Ancillary studies
Therapeutic Conventional Surgery
Undergo surgery
Parkview Hospital Randallia, Fort Wayne
City of Hope Medical Center, Duarte
City of Hope Upland, Upland
City of Hope Corona, Corona
National Cancer Institute (NCI)
NIH
City of Hope Medical Center
OTHER